Overview

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie